Abstract |
Transnasal butorphanol (TNB) is a mixed agonist- antagonist opioid that has recently been released for the treatment of painful conditions. Patients with a history of migraine diagnosed in either of two emergency departments (EDs) with a moderate or severe migraine were eligible for this prospective study. Patients received 1 mg of TNB at time zero and again in 45 minutes if needed. Twenty-five patients were studied. Pain intensity was measured on a 10-cm visual analog scale. Mean pain intensity was significantly decreased at 15 minutes and declined from 7.9 +/- 1 cm initially to 2.5 +/- 3.3 cm at 90 minutes. Sixty percent of the patients required no further treatment. Thirty-six percent experienced side effects, with all but 1 being mild or moderate. Seventy-five percent rated the treatment as good, very good, or excellent, and 71% would prefer to receive TNB for future migraines over other treatment options. TNB offers rapid, effective pain relief to the majority of ED migraine patients.
|
Authors | S W Melanson, J W Morse, D J Pronchik, M B Heller |
Journal | The American journal of emergency medicine
(Am J Emerg Med)
Vol. 15
Issue 1
Pg. 57-61
(Jan 1997)
ISSN: 0735-6757 [Print] United States |
PMID | 9002572
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Analgesics, Opioid
- Narcotic Antagonists
- Butorphanol
|
Topics |
- Administration, Intranasal
- Adult
- Analgesics, Opioid
(administration & dosage, therapeutic use)
- Butorphanol
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Migraine Disorders
(drug therapy)
- Narcotic Antagonists
(administration & dosage, therapeutic use)
- Pain Measurement
- Patient Satisfaction
- Prospective Studies
- Treatment Outcome
|